Noubar Afeyan’s Post

So proud Kaydee M. works at a great company.

Looking forward to attending #BioFuture2024 tomorrow to address how AI is revolutionizing the healthcare landscape. I welcome the opportunity to be part of an insightful conversation to discuss how we can embrace new technologies to accelerate the drug discovery and development process as we collectively strive to address unmet patient needs. #First4Patients.

Insight Partners Leads $105M Series B Funding for Notable Labs Congratulations to Notable Labs on their impressive $105 million Series B funding round, led by Insight Partners! Their pioneering work in predictive precision medicine is transforming the healthcare landscape by developing tailored treatments based on genomic data and machine learning. Learn more about their strategic milestones, partnerships, and what this investment means for the future of healthcare. #AIinHealthcare #HealthTechStartups #PrecisionMedicine #Investing

Look Dr. Ruth Gross up! I assure you will have an interesting and insightful conversation on our innovative AI driven computational platforms. #israelinnovation #evogen #decodingbiology

🤔 Have you explored TrialPioneer™️ yet? Our intuitive, free tool leverages extensive datasets from actual patient populations to enable quick comparisons between traditional vs AI-powered trial designs. #TrialPioneer offers insights that can significantly reduce trial timelines and costs, ensuring that groundbreaking treatments reach patients sooner. 🚀 Explore the possibilities today: https://lnkd.in/gXYN-nZ3

Yesterday, S2N Health CEO Amy Siegel moderated an all-star, all-women panel on funding for emerging medtech companies, with panelists Gwen Watanabe, Cynthia Yee, Virginia Giddings and Lori Chmura representing perspectives from venture, strategic investors and start-ups. The lively discussion covered the challenges funding medtech innovations and actionable strategies for attracting strategic investors to early-stage funding rounds. The need for emerging companies to connect with the right #KOLs to build relationships with strategics was emphasized as a key factor to eventual M&A success. S2N’s AI intelligence platform #RepSignal is a powerful, efficient solution for companies to identify and strategically engage with KOLs as advisors, investigators and early adopters. Learn how #RepSignal can help you connect with game changing KOLs 👉 https://lnkd.in/evH5qusw

Igentify’s CIO and Co-Founder Elliott Greenspan recently joined Mike Ward of Clarivate on a roundtable to discuss challenges and opportunities associated with diagnostics. Tune in to explore the exciting future of diagnostics: 🧬 Lessons from COVID-19: What did we learn from ramping up testing? 🧬 Investment & Collaboration: How is this experience changing partnerships? 🧬 Precision Medicine: How are diagnostics paving the way for personalized treatments? 🧬 Challenges & Opportunities: Regulatory hurdles and advancements in patient care. https://lnkd.in/enpysrYX #diagnostics #webinar #precisionmedicine #geneticcounseling

🚀 Leal Health Launches Next Generation AI Solution 🚀 Our First-To-Market, Single-Point-of-Access technology is revolutionizing precision medicine, while addressing the 5 Social Determinants of Health & bridging the gap between cancer patients & pharma. Leal's Version 2.0 is the ONLY digital health solution being implemented by Sponsors from clinic through post-marketing: https://lnkd.in/eteamKCU Message me to learn more. #precisionmedicine #GenAI

Make large patient datasets actionable with PhenOM™! Dealing with large datasets is a challenging task.  Our team has years of expertise, and as a result, we have built OM1 PhenOM™!  A core product built on patented technology that reliably, and repeatedly extracts insight from data and operationalizes those insights to make them actionable. PhenOM™ is also trained on OM1’s differentiated, high-quality data assets and built with expert clinician oversight. With PhenOM™, companies can gain insights into; 1. Diagnostic Insights: Find patients with rare, undiagnosed, or misdiagnosed conditions, including subgroups. 2. Treatment Insights: Identify patients who respond to particular treatments to improve access and guideline adherence.  3. Risk Insights: Predict risk of specific outcomes: disease progression, complications, and catastrophic events. 4. Utilization Insights: Isolate patients who are more likely to generate higher utilization, and utilization growth, over time.  5. Clinical Trials: Isolate patients who are more likely to generate higher utilization, and utilization growth, over time. OM1, Inc. will be attending Pharma USA 2024 on March 26-27, 2024 in Philadelphia, PA! Come meet the team (Andrew Wright, Monika J. Dziuba (Nowak), Lisa Rycyna MPH, and Kunal R. Chaudhary, Ph.D., MHA) to discover how OM1 utilizes AI in patient identification to find actionable insights and answer your most challenging questions. Are you interested in continuing the conversation? Book time with us here 📍https://lnkd.in/eJcKBAJK to meet onsite at Pharma USA 2024! #medicalaffairs #commercial #marketaccess #patientengagement #REpharmaUSA

I am really excited about this week's MedTech Minis episode. This week we sat down with Kyle McAllister, CEO and Co-Founder of Trially. Trially brings together it's deep knowledge of the #clinicaltrial landscape with cutting-edge #AI to offer unprecedented agility to research. Did you know that 86% of trials are delayed due to #recruitment issues. Trially allows you to super charge your candidate search using both #unstructured and #structured clinical data paired with industry-leading #AI for with amazing precision, speed and quality. Already saving one client well over 100 hours of time! Want to accelerate your clinical research? Learn more about Trially at https://trially.ai/ https://lnkd.in/gsZHh_da